Ono Pharmaceutical Sustainability Profile
Ono Pharmaceutical Co., Ltd., commonly referred to as Ono Pharma, is a prominent player in the biopharmaceutical industry, headquartered in Osaka, Japan. Founded in 1717, the company has a rich history of innovation, focusing on the research, development, and commercialisation of novel therapeutics, particularly in oncology, immunology, and pain management. Ono Pharma is renowned for its flagship product, Opdivo (nivolumab), a groundbreaking immunotherapy that has transformed cancer treatment paradigms. The company’s commitment to advancing healthcare is reflected in its robust pipeline and strategic partnerships, positioning it as a leader in the global pharmaceutical market. With a strong presence in Japan and expanding operations in North America and Europe, Ono Pharmaceutical continues to make significant strides in delivering unique and effective solutions for patients worldwide.
DitchCarbon Score
How does Ono Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ono Pharmaceutical's score of 78 is higher than 86% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ono Pharmaceutical's reported carbon emissions
In 2024, Ono Pharmaceutical reported total greenhouse gas emissions of approximately 15.1 million kg CO2e, comprising 8.1 million kg CO2e from Scope 1, 3.1 million kg CO2e from Scope 2, and approximately 3.9 million kg CO2e from Scope 3 emissions. The Scope 3 emissions included significant contributions from business travel (4.8 million kg CO2e) and upstream leased assets (1.7 million kg CO2e). Ono Pharmaceutical has set ambitious climate commitments, aiming for carbon neutrality for its Scope 1 and 2 emissions by FY2025, with a long-term goal of achieving zero greenhouse gas emissions by FY2035. These targets were brought forward from an initial 2050 deadline, reflecting a strong commitment to sustainability. The company also aims to reduce its absolute Scope 1 and 2 emissions by 55% by FY2030 and 100% by FY2050, using FY2017 as the baseline year. Additionally, it targets a 30% reduction in absolute Scope 3 emissions by FY2030 and 60% by FY2050. Ono Pharmaceutical's climate strategy aligns with industry standards, including commitments to the Science Based Targets initiative (SBTi), which validates its targets as consistent with the reductions required to limit global warming to 1.5°C. The company is actively working towards these goals, demonstrating a proactive approach to mitigating its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 22,100,000 | - | 0,000,000 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | - | - | - | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | - | - | - | 00,000,000 | - | 000,000,000 | 00,000,000 |
How Carbon Intensive is Ono Pharmaceutical's Industry?
How Carbon Intensive is Ono Pharmaceutical's Location?
Ono Pharmaceutical's Scope 3 Categories Breakdown
Ono Pharmaceutical's Scope 3 emissions, which decreased by 89% last year and decreased by approximately 85% since 2017, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 50% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 43% of Scope 3 emissions.
Top Scope 3 Categories
Ono Pharmaceutical's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ono Pharmaceutical has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Ono Pharmaceutical's sustainability data and climate commitments
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.